Mipsagargin: Interim Phase Ib/II data

Interim data from 20 evaluable HCC patients enrolled in either a dose-escalation Phase Ib trial or an open-label, U.S. Phase II trial showed IV G-202 led to a stable disease rate of 80%, including 10 patients with stable disease for >=4 months. Additionally, 1 patient with vertebral metastases had a significant reduction in bone pain. G-202 was generally well tolerated with increased alanine aminotransferase (ALT), bilirubin and creatinine levels, fatigue, hyperkalemia and hyperglycemia reported as the most common adverse events. Data were presented at the International Liver Cancer Association meeting in Kyoto. Patients in the Phase Ib trial received 40 mg/m 2 G-202 on day 1 followed by 66.8 mg/m 2 G-202 on days 2 and 3 of each 28-day cycle. The Phase II trial is evaluating 40 mg/m 2 G-202 on days 1-3 of each 28-day cycle in patients who had previously progressed on or who were intolerant of Nexavar sorafenib. ...